John Eriksson

John Eriksson

Auto-generated profile, based on publicly available information

John Eriksson

Department of Surgical Sciences Uppsala University Uppsala Sweden

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2011 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
ONOlov Norlén
Olov Norlén
Peter StålbergPeter Stålberg
Peter Stålberg
KÖKjell Öberg
Kjell Öberg
JEJohn Eriksson
John Eriksson
JHJakob Hedberg
Jakob Hedberg
GÅGöran Åkerström
Göran Åkerström

7 March 2008 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
JEJohn Eriksson
John Eriksson
Peter StålbergPeter Stålberg
Peter Stålberg
ANAnders Nilsson
Anders Nilsson
JKJohan Krause
Johan Krause
CLChristina Lundberg
Christina Lundberg
PHPer Hellman
Per Hellman

7 October 2019 in Scandinavian Journal of Surgery
Verified
Journal Article
Open access
PDF file
JEJ. Eriksson
J. Eriksson
ONO. Norlén
O. Norlén
MÖM. Ögren
M. Ögren
HGH. Garmo
H. Garmo
CIC. Ihre-Lundgren
C. Ihre-Lundgren
PHP. Hellman
P. Hellman
Background: Small intestinal neuroendocrine tumors are the most common of small bowel malignancies with a clinical incidence of about 1 per 100,000 persons per year. There has been a threefold increase in the incidence of small intestinal neuroendocrine tumor during later decades, but there are no studies that clarify whether this is due to a true higher incidence or if the rise is a mere product of, for instance, improved diagnostic modalities. The aim of this study was to investigate the incidence of clinical as well as subclinical small intestinal neuroendocrine tumors found at autopsy as well as describing the frequency of concomitant malignancies in patients with small intestinal neuroendocrine tumor. Materials and methods: An autopsy registry from the Malmö county population from 1970 to 1982 with an 87% autopsy rate was used. The clinical autopsy reports for patients coded for the existence of “carcinoid tumor” were scrutinized for the presence of small intestinal neuroendocrine tumor, metastatic disease, and concomitant malignancies. Details of patients with clinically diagnosed small intestinal neuroendocrine tumor during this time period were gathered from the Swedish Cancer Registry. Results: The mean annual incidence of small intestinal neuroendocrine tumor during this period was 5.33 per 100,000 individuals, and the mean annual prevalence was 581 per 100,000. The cause of death in the majority of cases was not due to small intestinal neuroendocrine tumor. In total, 48% of the people with small intestinal neuroendocrine tumor had at least one other malignancy, most commonly colorectal cancer. Conclusion: Most small intestinal neuroendocrine tumors are subclinical, and persons living with them will often die due to other causes. There was a high rate of multiple primary tumors (40%), suggesting that multiple tumors seem to arise before the advent of metastatic disease. Moreover, a comparably high rate of associated colorectal carcinoma was found.

30 November 2016 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JEJohn Eriksson
John Eriksson
HGHans Garmo
Hans Garmo
PHPer Hellman
Per Hellman
CICatharina Ihre-Lundgren
Catharina Ihre-Lundgren
Small intestinal neuroendocrine tumors (SI-NETs) are uncommon tumors with an annual incidence of about 1 per 100,000. Usually, SI-NETs have a slow progress

28 May 2018 in BJS Open
Verified
Journal Article
Open access
PDF file
JEJ. Eriksson
J. Eriksson
JGJ. E. H. Garmo
J. E. H. Garmo
CIC. Ihre-Lundgren
C. Ihre-Lundgren
PHPer Hellman
Per Hellman
Background Neuroendocrine tumours of the small intestine (SI‐NETs) are rare gastrointestinal neoplasms with an annual incidence of about one per 100 000. Patients with apparently similar tumours have variable outcomes. The aim of this study was to identify postoperative prognostic factors identifiable after initial surgery. Methods This was a nested case–control study of patients with SI‐NETs who were treated between 1961 and 2001. Data were retrieved from the Swedish Cancer Registry. Patients who died from the SI‐NET and corresponding controls (who outlived cases by at least 1 month), matched by age at diagnosis and calendar period, were included. Sex, postoperative symptoms, postoperative 5‐hydroxyindoleacetic acid (5‐HIAA) values, European Neuroendocrine Tumor Society (ENETS) stage, insufficiency of the tricuspid valve, radical secondary surgery and secondary malignancy were studied as potential prognostic factors. Results In total, 1122 patients were included (561 cases, 561 controls). Postoperative factors of prognostic importance included hormone‐related symptoms, stage IV disease, raised levels of 5‐HIAA, insufficiency of the tricuspid valve, secondary surgery not being macroscopically radical and a second malignancy. Conclusion Stage and symptomatic disease are important prognostic factors in SI‐NET.